长寿补剂及其功效 | Peter Attia 博士

摘要

Peter Attia 博士与 Andrew Huberman 深入探讨了 NAD pathway（NAD 通路）及其在长寿中的作用，考察补充 NR、NMN 或静脉注射 NAD 是否具有延长寿命或健康寿命的有意义的科学依据。对话涵盖了更广泛的长寿干预框架——从行为干预到雷帕霉素等抗衰老分子——并对流行长寿补剂背后的证据（或其缺失）进行了严格评估。

核心要点

雷帕霉素是目前证据支持最充分的抗衰老分子，是唯一两种（另一种为热量限制）在多物种严格测试中被证实能延长寿命的干预手段之一。
NAD 水平随年龄下降，但真正下降的很可能是氧化还原潜力（NAD/NADH 比值），而非 NAD 总量，这使得补充 NAD 的理论依据变得复杂。
NR 和 NMN 未能在干预测试项目（ITP）中延长寿命，而 ITP 是目前最严格的哺乳动物长寿测试平台。
NR 的口服生物利用度高于 NMN，因为 NMN 因含有磷酸基团而无法直接穿过细胞膜；舌下含服 NMN 可在一定程度上绕过这一限制。
白藜芦醇尽管曾引发巨大热潮，但在所有有意义的寿命研究中均以失败告终，唯一的例外是一个涉及极度脂肪肝疾病的高度人工化小鼠模型。
统计学显著性 ≠ 临床显著性 —— 多项 NMN/NR 人体研究呈现出技术层面显著的结果，但对实际健康并无有意义的影响。
热量限制与去乙酰化酶（sirtuins）通过独立的平行通路发挥作用 —— 长期以来认为热量限制通过激活去乙酰化酶发挥作用的假设已被推翻。
ITP 仅验证了极少数分子：雷帕霉素、卡格列净（SGLT2 抑制剂）、阿卡波糖和 17-α 雌二醇（仅限雄性）在小鼠中延长了寿命；二甲双胍和 NR 均未通过验证。
血糖调节——独立于体重减轻之外——似乎是一个强有力的长寿信号，阿卡波糖和卡格列净均在未减轻体重的情况下延长了小鼠寿命。

详细笔记

长寿干预的四大类别

Attia 提出了一个思考长寿干预的框架：

基本行为投入 —— 睡眠、运动（2 区有氧训练、抗阻训练）和营养。每个人都在做这些事；关键在于是否以促进健康的方式进行。
疾病靶向分子 —— 直接降低心血管疾病、癌症、神经退行性疾病和代谢疾病风险的药物（如他汀类药物、PCSK9 抑制剂、SGLT2 抑制剂、GLP-1 激动剂）。
抗衰老保护分子 —— 针对独立于特定疾病的衰老标志物的化合物（如 rapamycin（雷帕霉素），靶向 mTOR）。
全面/激进叠加策略 —— 将以上所有方法结合使用，以 Bryan Johnson 等人为代表。

雷帕霉素与 mTOR 抑制

Attia 本人每周服用 8 mg 雷帕霉素，因口腔溃疡（约 10% 的使用者会出现）而采用大约 2 个月服药 / 1 个月停药的循环方案。
mTOR（雷帕霉素的哺乳动物靶点）是驱动细胞生长的主要营养感知通路；抑制该通路可模拟热量限制的部分效果。
雷帕霉素与热量限制是唯一两种在多种模式生物（酵母、线虫、果蝇和小鼠）中被证实能延长寿命的干预手段。
ITP 的里程碑实验表明，即使在 21 月龄（相当于 60 岁人类）才开始使用，雷帕霉素仍能延长寿命。
犬类衰老研究（由 Matt Kaeberlein 主导）预计将于 2026 年公布结果，将为更高级别哺乳动物提供关键证据。Attia 在 NIH 撤资后帮助填补了 250 万美元的资金缺口，使该研究得以延续。

去乙酰化酶（Sirtuins）与热量限制的误解

1990 年代末，Matt Kaeberlein 的实验室发现过表达 Sir2（一种去乙酰化酶）可延长酵母寿命。
另一项独立实验显示，热量限制也能延长酵母寿命——这引发了”热量限制通过去乙酰化酶发挥作用”的假说。
2004 年，Kaeberlein 和 Brian Kennedy 发表的一篇论文使用第三种酵母菌株，证明热量限制与去乙酰化酶过表达独立且叠加地延长了寿命——二者是平行通路，而非同一通路。
去乙酰化酶过表达在哺乳动物中延长寿命的唯一证据：一种过表达 SIRT6 的转基因小鼠——雄性小鼠寿命延长了 10–15%；雌性小鼠无效果。
去乙酰化酶激活被认为有益的下游效应：
- 改善线粒体生物合成
- 增强 DNA 修复
- 抑制 senescent cells（衰老细胞）的 SASP（衰老相关分泌表型）

白藜芦醇：一个警示故事

白藜芦醇因作为葡萄皮/红酒中的去乙酰化酶激活剂而声名大噪。
唯一显示其有益效果的小鼠研究使用了高度人工化的模型：小鼠被强制喂食极高脂肪饮食，直至脂肪肝侵占胸腔。白藜芦醇”拯救”了这些小鼠。
当 ITP 以原研究者推荐的剂量测试白藜芦醇时：对寿命毫无影响。
“法国悖论”的解释（红酒 → 白藜芦醇 → 长寿）站不住脚——要复制小鼠研究的效果，所需剂量相当于饮用与体重等量的葡萄酒。

NAD 通路：生物学基础

NAD（烟酰胺腺嘌呤二核苷酸）参与 500–600 条酶促通路，主要作为 electron transport chain（电子传递链）中的电子穿梭体（NAD ↔ NADH）——在此过程中不被消耗，仅循环利用。
少量 NAD 被去乙酰化酶用作 DNA 修复的底物——在此过程中实际被消耗。
NAD 水平随年龄下降（人体血液中四十年间约下降 20%；皮肤中约下降 60%；根据动物数据，大脑中约下降 15–20%）。
关键在于，2015 年发表于 PNAS 的一项研究发现，随着年龄增长 NAD 下降，NADH 也相应升高——这表明 NAD+NADH 总量相对稳定，真正下降的是氧化还原潜力，而非 NAD 绝对量。

NR vs. NMN vs. 静脉注射 NAD

关键结构差异：

NR（烟酰胺核糖苷） → 可直接穿过细胞膜；口服生物利用度良好
NMN（烟酰胺单核苷酸） → NR + 一个磷酸基团；口服时无法直接穿过细胞膜；磷酸基团在肠道中被切除，使其重新转化为 NR
静脉注射 NAD → 绕过肠道，但无口服生物利用度；费用高昂（每次输注 300–1,000 美元）

Attia 的个人方案：

每周服用 8 mg 雷帕霉素、PCSK9 抑制剂、苯哌酸（bempedoic acid）、SGLT2 抑制剂
每日服用舌下含服 NMN（约 1,500 mg），主要基于主观感受（精力、头发/指甲生长加速）——并非基于长寿证据
曾进行过约 5–6 次静脉注射 NAD；最初 10 分钟极度不适（胸部压迫感、腿部痉挛、恶心）；事后感觉有所改善，但他认为部分效果可归因于安慰剂效应

Huberman 的方案：

口服 NMN，有时也服用 NR
报告主观精力有所改善；承认这属于个例（n=1），且很可能与延长寿命无关

关于小鼠给药剂量的重要说明： 显示 NMN/NR 有效的小鼠研究所用剂量为 500–1,000 mg/kg。

English Original 英文原文

Supplements for Longevity & Their Efficacy | Dr. Peter Attia

Summary

Dr. Peter Attia and Andrew Huberman conduct a deep dive into the NAD pathway and its role in longevity, examining whether supplementing with NR, NMN, or intravenous NAD has meaningful scientific support for extending lifespan or healthspan. The conversation spans the broader framework of longevity approaches — from behavioral interventions to geroprotective molecules like rapamycin — and rigorously evaluates the evidence (or lack thereof) behind popular longevity supplements.

Key Takeaways

Rapamycin is the single most evidence-supported geroprotective molecule available, being one of only two interventions (alongside caloric restriction) proven to extend lifespan across multiple species in rigorous testing.
NAD levels decline with age, but what’s actually declining is likely redox potential (the NAD/NADH ratio) rather than total NAD, which complicates the rationale for supplementation.
NR and NMN have failed to extend lifespan in the Interventions Testing Program (ITP), the most rigorous mammalian longevity testing platform available.
NR is more bioavailable orally than NMN because NMN cannot cross the cell membrane directly due to its phosphate group; sublingual NMN bypasses this somewhat.
Resveratrol, despite enormous hype, failed in every meaningful lifespan study outside of one highly artificial mouse model involving extreme fatty liver disease.
Statistical significance ≠ clinical significance — several NMN/NR human studies showed technically significant results that had no meaningful real-world health impact.
Caloric restriction and sirtuins operate through independent, parallel pathways — the long-held assumption that CR works through sirtuin activation has been disproven.
The ITP has validated very few molecules: rapamycin, canagliflozin (SGLT2 inhibitor), acarbose, and 17-alpha estradiol (males only) have extended lifespan in mice; metformin and NR have not.
Blood glucose regulation — independent of weight loss — appears to be a robust longevity signal, as both acarbose and canagliflozin extended mouse lifespan without reducing body weight.

Detailed Notes

The Four Categories of Longevity Approaches

Attia proposes a framework for thinking about longevity interventions:

Essential behavioral inputs — sleep, movement (Zone 2 cardio, resistance training), and nutrition. Everyone does these; the question is whether they’re done in a health-promoting way.
Disease-targeting molecules — drugs that directly reduce the risk of cardiovascular disease, cancer, neurodegeneration, and metabolic disease (e.g., statins, PCSK9 inhibitors, SGLT2 inhibitors, GLP-1 agonists).
Geroprotective molecules — compounds that target Hallmarks of Aging independent of specific disease (e.g., rapamycin, targeting mTOR).
Comprehensive/aggressive stacking — combining all of the above, as exemplified by figures like Bryan Johnson.

Rapamycin & mTOR Inhibition

Attia personally takes 8 mg of rapamycin once per week, cycling approximately 2 months on / 1 month off due to canker sores (affecting ~10% of users).
mTOR (mammalian target of rapamycin) is the primary nutrient-sensing pathway driving cellular growth; its inhibition mimics aspects of caloric restriction.
Rapamycin and caloric restriction are the only two interventions proven to extend lifespan across multiple model organisms (yeast, worms, flies, and mice).
The landmark ITP experiment showed rapamycin extended lifespan even when started at 21 months of age (~equivalent to a 60-year-old human).
The dog aging study (led by Matt Kaeberlein) is expected to report results in 2026 and will provide critical evidence in a higher-order mammal. Attia helped close a $2.5M funding gap to keep the study alive after NIH funding was pulled.

Sirtuins & the Caloric Restriction Myth

In the late 1990s, Matt Kaeberlein’s lab showed overexpressing Sir2 (a sirtuin) extended yeast lifespan.
A separate experiment showed caloric restriction also extended lifespan in yeast — leading to the hypothesis that CR works through sirtuins.
A 2004 paper by Kaeberlein and Brian Kennedy used a third yeast strain and showed CR and sirtuin overexpression independently and additively extended lifespan — they are parallel pathways, not the same pathway.
The only mammalian evidence for sirtuin overexpression extending lifespan: one transgenic mouse overexpressing SIRT6 — male mice lived 10–15% longer; female mice showed no effect.
Downstream effects of sirtuin activation believed to be beneficial:
- Improved mitochondrial biogenesis
- Enhanced DNA repair
- Suppression of SASP (senescence-associated secretory phenotype) from senescent cells

Resveratrol: The Cautionary Tale

Resveratrol gained fame as a sirtuin activator found in grape skins/red wine.
The one mouse study showing benefit used a highly artificial model: mice force-fed extreme high-fat diets until fatty livers encroached on their thoracic cavity. Resveratrol “rescued” these mice.
When the ITP tested resveratrol at doses recommended by the original researchers: no effect on lifespan whatsoever.
The “French paradox” explanation (red wine → resveratrol → longevity) is invalid — the doses needed to replicate mouse studies would require drinking body-weight quantities of wine.

The NAD Pathway: Biology

NAD (nicotinamide adenine dinucleotide) is involved in 500–600 enzymatic pathways, primarily as an electron shuttle (NAD ↔ NADH) in the electron transport chain — not consumed, just recycled.
A small fraction of NAD is used as a substrate by sirtuins for DNA repair — it is actually consumed in this process.
NAD levels decline with age (~20% reduction in blood over four decades in humans; ~60% decline in skin; ~15–20% in brain, based on animal data).
Critically, a 2015 PNAS study found that as NAD declines with age, NADH rises proportionally — suggesting total NAD+NADH is relatively stable, and what’s declining is redox potential, not absolute NAD.

NR vs. NMN vs. IV NAD

Key structural difference:

NR (nicotinamide riboside) → can cross cell membranes directly; orally bioavailable
NMN (nicotinamide mononucleotide) → NR + a phosphate group; cannot cross cell membranes directly when taken orally; the phosphate is cleaved in the gut, converting it back to NR anyway
IV NAD → bypasses gut but is not orally bioavailable; expensive ( $300-$ 1,000/infusion)

Attia’s personal protocol:

Takes 8 mg rapamycin/week, PCSK9 inhibitor, bempedoic acid, SGLT2 inhibitor
Takes sublingual NMN (~1,500 mg/day), primarily for subjective effects (energy, faster hair/nail growth) — not based on longevity evidence
Has done IV NAD infusions (~5–6 times); first 10 minutes are deeply uncomfortable (chest pressure, leg cramps, nausea); feels better afterward but attributes some of this to placebo

Huberman’s approach:

Takes oral NMN and sometimes NR
Reports subjective energy improvement; acknowledges this is anecdotal (n=1) and likely unrelated to lifespan extension

Important note on mouse dosing: Studies showing NMN/NR efficacy in mice use 500–1,000 mg/kg.

Health & Wellness | 健康知识库

健康导航 Navigation

长寿补剂及其功效 | Dr. Peter Attia